These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9356209)

  • 1. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis.
    Zeneroli ML; Venturini I; Stefanelli S; Farina F; Miglioli RC; Minelli E; Amedei ER; Ferrieri A; Avallone R; Baraldi M
    Pharmacol Res; 1997 Jun; 35(6):557-60. PubMed ID: 9356209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hepatic encephalopathy: role of rifaximin.
    Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
    Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study.
    Venturini I; Ferrieri A; Farina F; Cosenza F; Avallone R; Corsi L; Baraldi M; Zeneroli ML
    Drugs Exp Clin Res; 2005; 31(4):161-8. PubMed ID: 16223206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
    Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
    Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
    Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
    Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
    Kimer N; Pedersen JS; Tavenier J; Christensen JE; Busk TM; Hobolth L; Krag A; Al-Soud WA; Mortensen MS; Sørensen SJ; Møller S; Bendtsen F;
    J Gastroenterol Hepatol; 2018 Jan; 33(1):307-314. PubMed ID: 28671712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of rifaximin in the treatment of hepatic encephalopathy].
    Sanchez-Delgado J; Miquel M
    Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
    Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
    Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of hepatic encephalopathy in cirrhosis.
    Romero-Gómez M
    Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
    Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.
    Garcovich M; Zocco MA; Roccarina D; Ponziani FR; Gasbarrini A
    World J Gastroenterol; 2012 Dec; 18(46):6693-700. PubMed ID: 23239905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy.
    Baraldi M; Avallone R; Corsi L; Venturini I; Baraldi C; Zeneroli ML
    Metab Brain Dis; 2009 Mar; 24(1):81-93. PubMed ID: 19082698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
    Miglio F; Valpiani D; Rossellini SR; Ferrieri A
    Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
    Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
    Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.